🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 75% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

3 Capsule(s) Serving Size
60 Servings
Multi-Vitamin and Mineral (MVM) Product Type
75% Evidence Coverage

Supplement Facts — Evidence Check

25 mcg (125% DV)
✅ 1.7× RDA — within safe limits 📚 604 studies (Tier A: 16, B: 251)
RDA 0.015mg This product: 0.025mg UL 0.1mg
Calcium
500 mg (38% DV)
250 mg (60% DV)
📊 Market median: 4002.0mg (1 products) 📚 20 studies (Tier A: 0, B: 2)
This product: 250mg
22.5 mcg
✅ Within RDA (0.2× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.0225mg

Other Ingredients

Cellulose L-Leucine

Label Claims — Verification

Nutrient
All Other
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years) Gluten Free Dairy Free

Product Information

📋 Directions for Use

Directions: Three (3) capsules, one to two (1-2) times daily, or as directed by a healthcare professional.

⚠️ Warnings & Precautions

Caution: Individuals taking blood-thinning medications, please consult your healthcare professional before use.

Keep tightly closed in a cool, dry place, out of the reach of children.

🧪 Formulation Notes

Egg free Gluten free Free of nuts Dairy free

Manufactured in a GMP Compliant Facility

Additional Information

Keep tightly closed in a cool, dry place, out of the reach of children.

Product Details

UPC / SKU 8 38287 00409 7
DSLD Entry Date 2025-01-23
Product Type Multi-Vitamin and Mineral (MVM)
Form Capsule
DSLD ID 321271
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →